\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Mathematical Modeling for the Development of a Multilevel "Electronic Physician Assistant" and Simplified Assignment of Corrective Therapy to Immunocompromised Patients}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2021 2021-05-15 (revised: 7 Year 2021 15 May 2021)} \def\TheID{10.34257/GJMRKVOL21IS1PG1\makeatother } \def\TheDate{2021 2021-05-15} \title{Mathematical Modeling for the Development of a Multilevel "Electronic Physician Assistant" and Simplified Assignment of Corrective Therapy to Immunocompromised Patients} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Zemskov V.M., Zemskov A.M., Neymann V., Kozlova M.N., Alekseev A.A., Pronko K.N., Zemskova V.A., Demidova V.S., Revishvili A. Sh.} \renewcommand\Authands{ and } \date{\small \em Received: 14 April 2021 Accepted: 30 April 2021 Published: 15 May 2021} \maketitle \begin{abstract} The development of a multilevel "electronic doctor's assistant" for identifying immunologically compromised persons and the choice of optimal differentiated immunotherapy for pyo-inflammatory and other diseases is outlined. \end{abstract} \keywords{mathematical modeling, pre-laboratory analysis, immunopathological syndrome, immune correction.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \begin{textblock*}{10cm}(1.05cm,3cm) {{\textit{CrossRef DOI of original article:}} \underline{10.34257/GJMRKVOL21IS1PG1}} \end{textblock*}\let\tabcellsep& \section[{Introduction}]{Introduction}\par ne of the achievements of modern medicine is the development of principles for prescribing immunotherapy to patients, consisting of assessing the immune status, verifying the diagnosis of the underlying disease, comparing the signaling mechanisms of pathology and targets of the modulator, and testing the correction option in practice. Considering the certain complexity of the implementation of the above technologies, permission was given to develop a simplified algorithm for identifying the main immunopathological syndromes by the questionnaire method, to carry out auxiliary corrective therapy with traditional drugs, and to simplify the appointment of targeted immunotherapy to patients based on a set of programs for the Electronic Computing Machine, taking into account the laboratory examination of patients. \hyperref[b9]{1,} {\ref 2,} {\ref 3,} {\ref 4} II. \section[{Pre-Laboratory Analysis a) Identification of immunocompromised persons by the method of pre-laboratory analysis}]{Pre-Laboratory Analysis a) Identification of immunocompromised persons by the method of pre-laboratory analysis}\par Table {\ref 1} shows questionnaires for identifying 11 immunopathological syndromes, which include a predisposition to immune disorders, secondary immunodeficiency, infectious bacterial, viral, allergic, pseudo-allergic, metabolic, autoimmune and immunocomplex, lymphoproliferative, other syndromes, and concomitant chronic and combined diseases and conditions. {\ref 5} Table {\ref 1}: Immunopathological syndromes I. Immune Disorder Predisposition Syndrome 1. Professional harm. 2. Bad habits: smoking, alcohol, drug addiction, substance abuse, etc. 3. Frequent cooling, overheating, change of climatic zones. 4. Metabolic disorders, obesity. 5. Transfer in the last 3-6 months of great stress, burns, poisoning, physical exertion, radiation. 6. Risk groups -childhood, pregnancy, childbirth, menopause, old age. 7. Long-term stay in isolated spaces (prisons, submarines, spaceships). 8. Transplantation of foreign organs, tissues, implants. II. Secondary Immunodeficiency Syndromes 1. Syndrome of immune deficiency in children 1 year of life, is manifested by frequent, chronic infectious lesions of opportunistic pathogens, low virulent flora, viruses, chlamydia. 2. The syndrome of immunodeficiency in the elderly is manifested by frequent viral, bacterial, fungal infections of the bronchopulmonary, digestive, and genitourinary systems. 3. Syndrome of general variable immunodeficiency, which implies protracted recurrent bacterial infections of the respiratory, intestinal tracts, paranasal sinuses. 4. Post-tonsillectomy syndrome, which is characterized by recurrent infections of the nasopharynx, upper respiratory tract, hyperplasia of the lymphoid tissue of the nasopharynx. 5. Post-splenectomy syndrome with increased sensitivity to a wide range of infections. 6. Post-appendicectomy syndrome, manifested by chronic infections of the intestinal tube, dysbiosis. 7. Medical factors, which include surgery, anesthesia, antibiotics, nitrofurans, alkylating derivatives, corticosteroids, antimetabolites, drugs. III. Infectious Bacterial Syndrome 1. The frequency of infectious diseases is more than 3-4 times a year in adults, more than 6 times in children. 2. Atypical temperature reaction in case of an infectious disease. 3. Chronic pustular diseases of the skin, subcutaneous fatty tissue, soft tissues (furunculosis, sycosis, abscesses, lymphadenitis, phlegmons, proctitis, paraproctitis). 4. Gastrointestinal infections (gastroenteropathy, chronic diarrhea, dysbiosis, cholecystitis, pancreatitis). 5. Chronic lesions of the urogenital tract (pyelonephritis, cystitis, chlamydia, gardnerellas, mycoplasmosis, Reiter's syndrome). 6. Chronic infections of ENT organs (sinusitis, frontal sinusitis, gaymority, purulent otitis media). 7. Purulent keratoconjunctivitis. 8. Torpid to treatment recurrent aphthous stomatitis. 9. Specific infections tuberculosis, toxoplasmosis, brucellosis, leprosy, syphilis, malaria. 10. Sepsis, septicopyemia, peritonitis, abscesses of the lungs, and other organs. IV. Infectious Viral Syndrome 1. Frequent relapses of viral infections. 2. Refractoriness, i.e. resistance of viral diseases to traditional therapy. 3. Prolonged low-grade fever, unmotivated lymphadenopathy, chronization of infectious processes. 4. Persistent viral infections -cytomegalovirus, herpes, caused by the Epstein-Barr virus, Dengue fever, chronic viral hepatitis (B and C). 5. Persistently recurrent clinical manifestations of papillomatosis and candilomatosis against the background of ongoing standard therapy. 6. Chronic fatigue syndrome, which occurs in young women and men. 7. Risk groups of ARVI. These include newborn babies, early age, with late-onset of reactivity, low body weight, and those born during pathological pregnancy. These are older children with chronic diseases of the heart, lungs, kidneys, etc. V. Other Infectious Syndromes 1. Mycoses (superficial, subcutaneous, systemic, opportunistic). 2. Lesions with protozoa (trypanosomes, leishmania, lamblia, trichomonad, malaria plasmodium, toxoplasma, intestinal balantidia). 3. Defeats by intracellular parasites (chlamydia, gardnerella, mycoplasma, ureaplasma). \section[{b) Interpretation of the results of the analysis of the prelaboratory examination of patients}]{b) Interpretation of the results of the analysis of the prelaboratory examination of patients}\par It concerns the syndrome of susceptibility to immune disorders, displayed when there are three positive answers to any question in the questionnaire. This also includes immunodeficiency, infectious, pseudo-allergic syndromes, and a syndrome of combined and accompanying diseases, presented with a positive answer to two questions of the questionnaire. And, finally, autoimmune, lymphoproliferative, allergic, and metabolic syndromes, which are displayed with a positive answer to one question of the corresponding questionnaires. \section[{c) Options for the conclusion based on the results of the survey}]{c) Options for the conclusion based on the results of the survey}\par According to these results, the patient belongs to a risk group for predisposition or immunodeficiency syndromes and a high-risk group for allergic, autoimmune, lymphoproliferative, or the same, with a combination of several immunopathological syndromes. \section[{III. Syndromic Appointment of Auxiliary Immunotherapy}]{III. Syndromic Appointment of Auxiliary Immunotherapy}\par Auxiliary immunotherapy involves the use of traditional medicines with an immunotropic effect in the treatment of patients. When choosing antibacterial drugs, in addition to their antibiotic sensitivity to pathognomonic microflora, it is recommended to take into account their immunosuppressive effect, for example, in Abactal, Ampicillin, Isoniazid, Kanamycin, Chloramphenicol, Monomycin, PASK, Pyrazinamide, Rifampicin, Streptomycin, Tetracycline, Furacillin, Furagin, and immunostimulating activity, as in the case of Erythromycin, Miramistin, Nizoral, Nystatin, Levin, Roxithromycin, Amphotericin, Metacyclin, Bactrim, Macropen, Isoniazid, and Clindamycin. 8.9 \section[{e) Metabolic syndrome g) Elimination of metabolic disorders}]{e) Metabolic syndrome g) Elimination of metabolic disorders}\par It is carried out by energizers Riboflavin and Nicotinamide, glycolysis activators Thiamine and Riboxin, and the tricarboxylic acid cycle Biotin Lipoat. bronchial asthma + chronic pneumonia), or different genesis (autoimmune thyroiditis + obstructive pulmonary disease). Patients from this group, in addition to the basic treatment, receive "small" immune correctors. These include adaptogens (Manchurian aralia, Roseola Rosea, extracts from ginseng, Pantocrine, Eleutherococcus, Esberitox, tincture of Chinese magnolia vine) and metabolites, antioxidants, and vitamins (Riboxin, Potassium orotate, Hypoxenes, Reamberin, Tramelan, Pentoxyl, Methyluracil, Mildronate, Pantholex, vitamins of group B, C, A, E, Quercetin, Pangamic acid, Lipoic acid, Asparkam, brewer's yeast, Sodium nucleinate). The group of other drugs includes Piracetam, Polistim, Bendazole, Glutamic acid, Curantil, Apilac, Splenin, Leucogen, interferon, Cinnarizine, Zaditen. Finally, the eubiotics group consists of Acipol, Acylact, Bactisubtil, Bactobacterin, Bifacid, Bifibin, Bifilong, Bifidumbacterin, Bificol, Colibacterin, Biphilis, Lactobacterin, Vitanar, Linex, Narine, Sporobacterin. \section[{Combinations of immunopathological syndromes (infectious + allergic, immunodeficient + infectious). 4. Medicinal complications (dysbacteriosis, toxicosis, allergization, immune disorders).}]{Combinations of immunopathological syndromes (infectious + allergic, immunodeficient + infectious). 4. Medicinal complications (dysbacteriosis, toxicosis, allergization, immune disorders).} \section[{Mathematical}]{Mathematical} \section[{b) High-risk group}]{b) High-risk group}\par Patients of this group, in addition to traditional therapy, receive a combination of two or three small immunocorrectors or broad-spectrum modulators. The latter include Sodium nucleinate, Isoprinosine, thymus drugs, Myelopid, Levamisole, Hemodez, Reamberin, Splenin, Sanaviron, Leukinferon, Polyelectrolytes, Diucifon, etc. \section[{f) Dysnucleotidosis}]{f) Dysnucleotidosis}\par In this condition, Derinat, Ridostin, Sodium nucleinate, Riboxin, Potassium orotate, Methyluracil, Pentoxil, Asparkam (Panangin), Vitamin B6, Glycerophosphate, Folic acid, Hypoxene, Cygapan, Lemont, and Tikveol are quite effective. \section[{d) Infectious viral syndrome}]{d) Infectious viral syndrome}\par In this case, it is permissible to use a combination of two or three drugs. The list includes Dibazol, Interferon, Kurantil, Quercitin, Leukinferon, Levamisole, Myelopid, Methyluracil, Pentoxil, Prodigiosan, Remantadin, Arbidol, Vitamin A, Diucifon, Acyclovir. For persistent viral hepatitis, respectively, Katergen, Piracetam, Leukinferon, Sodium nucleinate, Lipoic acid, Acyclovir, Ribamidil, Sirepar, Cycloferon, human ?-interferon, or recombinant genetically engineered human interferon Reaferon. \section[{i) Allergic syndrome j) Treatment principles}]{i) Allergic syndrome j) Treatment principles}\par They consist of (1) elimination of the allergen, (2) the use of agents that nonspecifically suppress allergic reactions, (3) nonspecific immunosuppressive therapy, (4) specific immunotherapy, (5) targeted immunomodulation, (6) non-drug immune correction. In practice, one principle of treatment is rarely used, mainly combinations of them are used. The tactics of treating patients significantly depend on the stage of the disease. So, in the period of exacerbation, therapy is aimed at eliminating acute clinical manifestations of an allergic reaction, and in the period of remission at preventing its progression. \section[{k) Pseudoallergic syndrome}]{k) Pseudoallergic syndrome}\par A variety of medications are used to relieve this condition. \section[{i. Antihistamines}]{i. Antihistamines}\par There are six groups of antihistamine compounds. These include (1) ethylenediamine, Suprastin, (2) ethanolamines, Diphenhydramine, (3) alkylamines, Dimethindene, (4) phenothiazine derivatives, Pipolfen, (5) piperazine derivatives, Cinnarizine, (6) antihistamines of various origins Tavegil, Fenkarol, Bicarfen, Peritol, Pernovin, Diazolin, Ketotyphene. \section[{l) H1 -2 nd generation antihistamines}]{l) H1 -2 nd generation antihistamines}\par These include Teldan, Claritin, Gismanal, Zirtek, Semprex, Avastin, Terfenadine, Astemizole, Cimetidine, etc. \section[{n) Choleretic drugs}]{n) Choleretic drugs}\par Which are Alcohol, Lyobil, Cholenzyme, decoctions of the sandy immortelle flower, immortelle extract, corn silk, Tanacehol, Konvaflavin, Flacumin, Oxyphenamide, and Tsikvalone. \section[{p) Eubiotics}]{p) Eubiotics}\par Various eubiotics, Acipol, Bactisubtil, Bactobacterin, Bifilong, Bifilis, Bifinormalizer, Bifidumbacterin, have also proved to be effective. q) Autoimmune syndrome i. Correction principles They consist of (1) Elimination of "forbidden" clones of sensitized lymphocytes, (2) Removal of an immunogen or an adjuvant. (3) Plasmapheresis, (4) Immunosuppressive therapy, (5) Blockade of mediators of immune responses with antihistamines, (6) Replacement therapy for pernicious anemia with vitamin B12, for myxedema thyroxine, (7) Prescription of antiinflammatory drugs, nonsteroidal drugs and salicylates, corticosteroids, (8) Prescription of cyclosporin A, (9) Immunotherapy using causative allergens, (10) Immunocorrection of T-suppressor deficiency, (11) Use of gammaglobulins (immunoglobulins) for intravenous administration, (12) Application monoclonal antibodies against proinflammatory cytokines, (13) Autologous hematopoietic stem cell transplantation against the background of high-dose immunosuppression, ( {\ref 14}) Gene therapy due to suppression of cytokine formation by genes transferred by viral vectors. It is essential to note that the effectiveness of the autoimmune syndrome correction is temporary and is expressed in remission. \section[{r) Lymphoproliferative syndrome i. Correction principles}]{r) Lymphoproliferative syndrome i. Correction principles}\par The main types of treatment for lymphoproliferative and malignant neoplasms are surgical, radiation, and drug actions, which have a suppressive effect on the immune system, and this is the basis for the appointment of the thymus, polysaccharide, nucleic acid drugs, interferons, and interferon genes, synthetic polyoxidonium stimulants, Dapsone, Lycopid, Levamisole, vitamins, as well as blood plasma, etc. \section[{IV. Simplified Purpose of Patients with}]{IV. Simplified Purpose of Patients with}\par Differentiated Immunotherapy based on the Software a) Unified immunotherapy This type of immunotherapy is implemented, taking into account the nature of the disease. {\ref 10,} {\ref 11,}\hyperref[b41]{12} The choice of options is carried out according to the formulas of disorders of the immune system (FDIS is compiled by selecting the most significantly altered immune parameters from the normal level) \hyperref[b9]{1} for specific diseases. The analysis of the immune status in patients may not be carried out because a verified clinical diagnosis of the disease, the key parameters of the previously defined typical FDIS for a specific isoform, Legend: FDIS is a formula for disorders of the immune system, built on three key parameters that are most different from the level of the norm, with an indication of the direction of the dynamics vector (+ hyperactivation, -deficiency) and the degree of these changes (1-3, where 1-I degree of changes is transient up to 33\% of the norm, 2-II degree is reliable from 34 to 66\%, 3-III degree highly significant> 66\%), L -leukocytes, RN -rod-nuclear neutrophils, IL -interleukins. ESR-erythrocyte sedimentation rate, NBTac- \section[{Legend: (C) cellular, T-dependent, (H) humoral, B-dependent, (N) nonspecific links of immunity, + target of positive action of the drug}]{Legend: (C) cellular, T-dependent, (H) humoral, B-dependent, (N) nonspecific links of immunity, + target of positive action of the drug} \section[{Legend: AF -absorption function (phagocytic index and number), MF -metabolic function (NBT-test spontaneous or activated), CIC-circulatory, immune complexes, MWM -medium-weight molecules, Tc-Lph -cytotoxic T-lymphocytes, + the effect of the drug is established}]{Legend: AF -absorption function (phagocytic index and number), MF -metabolic function (NBT-test spontaneous or activated), CIC-circulatory, immune complexes, MWM -medium-weight molecules, Tc-Lph -cytotoxic T-lymphocytes, + the effect of the drug is established} \section[{NBT-test activated, NBTsp-NBT-test spontaneous, TNF-tumor necrosis factor, Tc-T-cytotoxic lymphocytes, T-T-lymphocytes, Eeosinophil, Lph-lymphocytes, FI-phagocytic index}]{NBT-test activated, NBTsp-NBT-test spontaneous, TNF-tumor necrosis factor, Tc-T-cytotoxic lymphocytes, T-T-lymphocytes, Eeosinophil, Lph-lymphocytes, FI-phagocytic index}\par The algorithm for prescribing differentiated immunotherapy is that the recommended drugs are selected for patients with certain diseases based on the key parameters of FDIS by the tables given. For example, in acute pneumonia with FDIS constituting CD3 2 ¯IgM 2 ¯IgA 2 ¯ (deficiency of T-lymphocytes, IgA, and IgM of the second degree), the recommended drugs for correcting CD3 2 deficiency are autohemotherapy, vitamins, Viferon, etc. Regarding IgM 2 ¯, IgA 2 ¯ shows the same drugs, etc. \section[{b) Generalized immunotherapy}]{b) Generalized immunotherapy}\par It is used without considering the nature of the disease. {\ref 6} It is used in the severe clinical condition of patients. It is based on a generalized definition of altered links of immunity (by the presence of indicators with second-third degrees of immunodeficiency) and the choice of modulators based on grouped passport targets of action on individual links of the immune system without taking into account the nature of the diseases (Tables \hyperref[tab_1]{2, 5}). \section[{c) Interpretation of the results of the immune examination of patients}]{c) Interpretation of the results of the immune examination of patients}\par If one or more indicators coincide in a particular patient, grouped by immunity links with tabulated ones, a conclusion is made about the deficit of the secondthird degree of the link as a whole (Table {\ref 5}).\par Table {\ref 5}: Reference values of laboratory parameters, grouped by immunity links \section[{Legend: ?U-conventional units; PhI, PN -phagocytic index and number, other designations -see above d) Detailed immunotherapy}]{Legend: ?U-conventional units; PhI, PN -phagocytic index and number, other designations -see above d) Detailed immunotherapy}\par It is carried out without taking into account the nature of the disease. \hyperref[b42]{13} Specific critically reduced laboratory parameters of the second or third degree are determined in patients according to the table's values. Based on their coincidence with the passport targets of modulators, variants of detailed immunotherapy are selected. \section[{e) Algorithm for prescribing detailed immunotherapy}]{e) Algorithm for prescribing detailed immunotherapy}\par The changed indicator/indicators in a particular patient are determined if its value coincides with the tabular value of the modulator target. According to these data, specialized drugs are selected for a prescription that can act on these indicators. \section[{f) Personalized immunotherapy}]{f) Personalized immunotherapy}\par It is carried out, taking into account the nature of the disease. \hyperref[b43]{14,}\hyperref[b44]{15,}\hyperref[b45]{16,}\hyperref[b46]{17} The algorithm for choosing personalized immunotherapy is implemented according to certain formulas for the targets of immunoprotection (ITF, determined by the three most altered immune parameters from the initial level after performing immunocorrection) \hyperref[b9]{1} in certain diseases (Table \hyperref[tab_4]{6}). The essence of the program is that based on ITF, including the second-third degree of changes in laboratory signal parameters towards a decrease or increase, the key values of diagnostically significant immune parameters are selected, summarized in the tables. By comparing the data of laboratory examination of certain patients with tabular values, marker parameters changed from the normal level are revealed according to the vector and the degree of their changes. When the selected indicators coincide with the three key components of ITF for certain diseases, the optimal options for immunotherapy are selected, which are prescribed against the background of traditional basic treatment of diseases. Legend: DID, DIH-the degree of immune deficiency, the degree of immune hyperfunction, Nph -neutrophil, ESR-erythrocyte sedimentation rate, for other designations, see above.\par V. \section[{Conclusion}]{Conclusion}\par A certain problem of the current state of clinical immunology is the insufficient introduction of innovative diagnostic and therapeutic technologies into practice, which is often accompanied by not always full use of the latest immunotherapeutic effects in the treatment of patients and, as a consequence, their often insufficient effectiveness. This also includes the lack of simple and, at the same time, informative methods of immune diagnostics.\par One solution to the stated problem is the development at the first level of a simplified technology for the clinical detection of marker immunopathological syndromes with the appointment of profile "small" immunocorrectors to patients. At the second level, based on laboratory assessment of the reactivity of patients, created laboratory support and preliminary study of the effectiveness and targets of differentiated immunotherapy of certain diseases in work, mathematically justified unified, generalized, detailed, and personalized methods for choosing options for optimal immunotherapy are presented. ... They are a good help in the daily work of a practical clinical immunologist. \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.32195791399817014\textwidth}P{0.02566331198536139\textwidth}P{0.019441903019213176\textwidth}P{0.02333028362305581\textwidth}P{0.3826166514181153\textwidth}P{0.029551692589204023\textwidth}P{0.0202195791399817\textwidth}P{0.027218664226898445\textwidth}} Preparations\tabcellsep C\tabcellsep H\tabcellsep N\tabcellsep Preparations\tabcellsep C\tabcellsep H\tabcellsep N\\ Adaptogens\tabcellsep \tabcellsep \tabcellsep +\tabcellsep Ozonized sodium chloride\tabcellsep +\tabcellsep +\tabcellsep +\\ Anabol\tabcellsep +\tabcellsep \tabcellsep \tabcellsep Lysozyme\tabcellsep \tabcellsep \tabcellsep +\\ Autohemotherapy\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Methyluracil\tabcellsep +\tabcellsep +\tabcellsep +\\ \tabcellsep +\tabcellsep \tabcellsep \tabcellsep Myelopid\tabcellsep +\tabcellsep +\tabcellsep +\\ Acyclovir\tabcellsep +\tabcellsep \tabcellsep \tabcellsep Trace elements\tabcellsep +\tabcellsep +\tabcellsep +\\ Bronchomunal\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Leukomax\tabcellsep +\tabcellsep \tabcellsep \\ Vaccines\tabcellsep \tabcellsep +\tabcellsep \tabcellsep Likopid\tabcellsep +\tabcellsep +\tabcellsep +\\ Vitamin A\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep Sodium nucleinate\tabcellsep +\tabcellsep +\tabcellsep +\\ Vitamins B\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep Potassium orotate\tabcellsep +\tabcellsep \tabcellsep +\\ Vitamin C\tabcellsep \tabcellsep \tabcellsep +\tabcellsep Polyoxidonium\tabcellsep +\tabcellsep +\tabcellsep +\\ Viusid\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep Synthetic polynucleotides\tabcellsep +\tabcellsep +\tabcellsep +\\ Gammaglobulin\tabcellsep \tabcellsep +\tabcellsep \tabcellsep Plasma\tabcellsep +\tabcellsep \tabcellsep +\\ ?-interferon\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep Plasmapheresis\tabcellsep +\tabcellsep \tabcellsep +\\ Gepon\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Panavir\tabcellsep +\tabcellsep \tabcellsep +\\ Hemodez\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Piracetam\tabcellsep +\tabcellsep \tabcellsep \\ Hypoxene\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Plasmapheresis\tabcellsep +\tabcellsep +\tabcellsep +\\ Heparin\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep Polyelectrolytes\tabcellsep +\tabcellsep +\tabcellsep +\\ Glutoxim\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Pentoxil\tabcellsep +\tabcellsep +\tabcellsep +\\ Dalargin\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Pyrogenal\tabcellsep +\tabcellsep +\tabcellsep +\\ Derinat\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Preventan\tabcellsep +\tabcellsep +\tabcellsep +\\ Dibazol\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Prodigiosan\tabcellsep +\tabcellsep +\tabcellsep +\\ Diuciphon\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Reaferon\tabcellsep +\tabcellsep \tabcellsep \\ Diuciphon\tabcellsep +\tabcellsep \tabcellsep \tabcellsep Reopolyglyukin\tabcellsep +\tabcellsep +\tabcellsep +\\ Zixorin\tabcellsep \tabcellsep \tabcellsep +\tabcellsep Riboxin\tabcellsep +\tabcellsep \tabcellsep +\\ Isoprenosine\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Ridostin\tabcellsep +\tabcellsep +\tabcellsep +\\ Isoprenosine\tabcellsep \tabcellsep \tabcellsep +\tabcellsep Roncoleukin\tabcellsep +\tabcellsep +\tabcellsep +\\ Immunomax\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Ruzam\tabcellsep +\tabcellsep \tabcellsep +\\ Immunomax\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Splenin\tabcellsep +\tabcellsep +\tabcellsep +\\ Indomethacin\tabcellsep +\tabcellsep \tabcellsep \tabcellsep Superlimph\tabcellsep +\tabcellsep +\tabcellsep +\\ Lysate of bacteria IRS-19\tabcellsep \tabcellsep \tabcellsep +\tabcellsep Tamerid\tabcellsep +\tabcellsep +\tabcellsep +\\ Katergen\tabcellsep +\tabcellsep \tabcellsep \tabcellsep Thymus preparations\tabcellsep +\tabcellsep +\tabcellsep +\\ Camedon\tabcellsep \tabcellsep +\tabcellsep \tabcellsep Trichopolus\tabcellsep \tabcellsep \tabcellsep \\ Combined immune drug\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Body ultraviolet irradiation\tabcellsep \tabcellsep \tabcellsep +\\ Kipferon\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Ultraviolet blood irradiation\tabcellsep +\tabcellsep +\tabcellsep \\ Quercetin\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep Phenazepam\tabcellsep +\tabcellsep \tabcellsep +\\ Bloodletting\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Cycloferon\tabcellsep +\tabcellsep +\tabcellsep +\\ Leakadin\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Cinnarizine\tabcellsep +\tabcellsep \tabcellsep \\ Levamisole\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Cimetidine\tabcellsep +\tabcellsep \tabcellsep +\\ Leukinferon\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep Cygapan\tabcellsep +\tabcellsep +\tabcellsep +\\ Low-intensity laser radiation\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep Erythrocytes\tabcellsep +\tabcellsep +\tabcellsep +\end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.5206806282722514\textwidth}P{0.04116492146596859\textwidth}P{0.03671465968586387\textwidth}P{0.028926701570680627\textwidth}P{0.018913612565445024\textwidth}P{0.03226439790575916\textwidth}P{0.04339005235602094\textwidth}P{0.018913612565445024\textwidth}P{0.012238219895287958\textwidth}P{0.008900523560209424\textwidth}P{0.03226439790575916\textwidth}P{0.02781413612565445\textwidth}P{0.02781413612565445\textwidth}} Preparation\tabcellsep CD3+\tabcellsep CD4+\tabcellsep CD8+\tabcellsep CD16+\tabcellsep CD19+\tabcellsep Ig\tabcellsep CIC\tabcellsep MWM\tabcellsep CD11?\tabcellsep AF\tabcellsep MF\tabcellsep Tc-Lph\\ Autohemotherapy\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \\ Vitamins\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Viferon\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\\ Hemodez\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Hypoxene\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Gepon\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Glutoxim\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\\ Dalargin\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\\ Decaris/levamisole\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Derinat\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\\ Diuciphon\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Donor ?-globulin\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Isoprinosine\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Imudon\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Immunomax\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\\ Imunofan\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Combined immune preparation (CIP)\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\\ ?IPferon\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Leakadin\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Leukinferon\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Likopid\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \\ Limontar\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \\ Therapeutic plasmapheresis\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Myelopid\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\\ Neovir\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Low-intensity laser radiation\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\\ Sodium nucleinate\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Ozone\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Polystim\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ Polyoxidonium\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Polysaccharides\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Ridostin\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Sorbents\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \\ Splenin\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\\ Superlimph\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Tamerid\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\\ Thymomimetic\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep +\\ Tikveol\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep \\ Ultraviolet blood irradiation\tabcellsep \tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \\ Cygapan\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep +\tabcellsep \tabcellsep \\ Esberitox\tabcellsep +\tabcellsep +\tabcellsep +\tabcellsep \tabcellsep +\tabcellsep +\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep +\tabcellsep \end{longtable} \par \caption{\label{tab_2}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4} \par \begin{longtable}{P{0.5116059379217274\textwidth}P{0.038427800269905533\textwidth}P{0.2982456140350877\textwidth}P{0.000573549257759784\textwidth}P{0.001147098515519568\textwidth}} \multicolumn{2}{l}{Diseases}\tabcellsep FDIS\\ \multicolumn{2}{l}{I. Bronchopulmonary diseases}\tabcellsep \\ Acute pneumonia\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 2 ¯IgM 2 ¯IgA 2 ¯}\\ Chronic pneumonia in adults\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 3 ¯IgA 2 ¯Ig? 2 ¯}\\ Chronic pneumonia in children\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯Ig? 2 ¯}\\ \multicolumn{2}{l}{The mixed form of bronchial asthma in adults}\tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯IgA 2 ¯}\\ Exogenous bronchial asthma\tabcellsep \tabcellsep \multicolumn{2}{l}{Lph 2 + ?D4 2 ¯?D3 2 ¯}\\ Endogenous bronchial asthma\tabcellsep \tabcellsep \multicolumn{2}{l}{RN 2 + ?D3 2 ¯NBTsp 2 +}\\ \multicolumn{2}{l}{The mixed form of bronchial asthma in children}\tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D4 2 ¯?D8 2 ¯}\\ \multicolumn{2}{l}{Corticosteroid bronchial asthma in adults}\tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯IgA 3 ¯}\\ \multicolumn{2}{l}{The mixed form of bronchial asthma, stage of exacerbation}\tabcellsep L 2 + ?D4 2 ¯?D3 2 ¯\\ \multicolumn{2}{l}{The mixed form of bronchial asthma, stage of remission}\tabcellsep \multicolumn{2}{l}{RN 3 + ?D19 2 ¯MWM 2}\tabcellsep +\\ Chronic bronchitis\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯IgA 3 ¯}\\ \multicolumn{2}{l}{Chronic obstructive pulmonary disease}\tabcellsep \multicolumn{2}{l}{?D4 3 ¯?D8 3 + CIC 3 +}\\ Infectious destruction of the lungs\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯IgA 3 ¯}\\ Chronic obstructive bronchitis\tabcellsep \tabcellsep \multicolumn{2}{l}{?D3 2 ¯?D19 2 ¯IgA 2 ¯}\\ II.\tabcellsep Purulent-inflammatory diseases\tabcellsep \\ Deep pyoderma\tabcellsep \tabcellsep \multicolumn{2}{l}{IL8 3 + CIC 3 + NBT?c 3 ¯}\\ Purulent soft tissue infection\tabcellsep \tabcellsep \multicolumn{2}{l}{?D8 3 + E 3 + ?D19 2 ¯}\\ Acute salpingo-oophoritis\tabcellsep \tabcellsep L 3 + CIC 3 + ?D4 2 ¯\\ \multicolumn{2}{l}{Exacerbation of chronic salpingo-oophoritis}\tabcellsep ?c 3 + IL8 3 + ? 3 +\\ Acute pyelonephritis\tabcellsep \tabcellsep IgG + 3 MWM + 3 L +\tabcellsep 2\\ \multicolumn{2}{l}{Exacerbation of chronic pyelonephritis}\tabcellsep \multicolumn{2}{l}{ESR 3 + IgG 3 + ?D8 3}\tabcellsep +\\ \multicolumn{2}{l}{Exacerbation of chronic calculous pyelonephritis}\tabcellsep \multicolumn{2}{l}{?D4 2 ¯?D3 2 ¯FI 2 ¯}\\ \multicolumn{2}{l}{Exacerbation of chronic non-calculous pyelonephritis}\tabcellsep \multicolumn{2}{l}{?D8 2 ¯?D19 2 ¯?D3 2 ¯}\\ \multicolumn{2}{l}{Exacerbation of chronic salpingo-oophoritis + cervicitis}\tabcellsep \multicolumn{2}{l}{E 3 + ?D3 2 ¯?D3 2 +}\\ Cervicitis\tabcellsep \multicolumn{3}{l}{HLA-DR-Lph 2 + ?D3 2 ¯?D19 2 ¯IgA 2 ¯}\\ Exacerbation of chronic cystitis\tabcellsep \tabcellsep \multicolumn{2}{l}{IgG 3 + NBT?c 3 ¯TNF 3 +}\end{longtable} \par \caption{\label{tab_3}Table 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{6} \par \begin{longtable}{P{0.85\textwidth}} Year 2021\\ 9\end{longtable} \par \caption{\label{tab_4}Table 6 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{7} \par \begin{longtable}{P{0.33584384858044164\textwidth}P{0.17764195583596215\textwidth}P{0.08647476340694006\textwidth}P{0.15887223974763406\textwidth}P{0.09116719242902208\textwidth}} Immune phenotypic and functional\tabcellsep \multicolumn{4}{l}{Immune System Disorders Formulas (FDIS)}\\ characteristics\tabcellsep 2 DID(-2)\tabcellsep 3 DID(-3)\tabcellsep 2 DIH(+2)\tabcellsep 3 DIH(+3)\\ ?-Lph (CD45+CD3+), 10 9 /l\tabcellsep 0,5-1,0\tabcellsep <0,5\tabcellsep 2,0-2,5\tabcellsep >2,5\\ ?-helpers (CD45+CD3+CD4+), 10 9 /l\tabcellsep 0,38-0,74\tabcellsep <0,38\tabcellsep 1,46-1,82\tabcellsep >1,82\\ T-cytotoxic Lph(CD45+CD3+CD8+), 10 9 /l\tabcellsep 0,14-0,28\tabcellsep <0,14\tabcellsep 0,56-0,7\tabcellsep >0,7\\ T-activated Lph(?D3+HLA-DR), 10 9 /l\tabcellsep 0,04-0,08\tabcellsep <0,04\tabcellsep 0,16-0,2\tabcellsep >0,2\\ T-regulatory Lph(?D3+?D4+?D25+), 10 9 /l\tabcellsep 0,03-0,07\tabcellsep <0,03\tabcellsep 0,15-0,19\tabcellsep >0,19\\ NK-cytolytic(?D3-?D16+?D56+), 10 9 /l\tabcellsep 0,04-0,08\tabcellsep <0,04\tabcellsep 0,16-0,2\tabcellsep >0,2\\ ?-Lph (CD19+), 10 9 /l\tabcellsep 0,2-0,4\tabcellsep <0,2\tabcellsep 0,4-0,6\tabcellsep >0,6\\ Ig?, g/l\tabcellsep 0,6-1,3\tabcellsep <0,6\tabcellsep 3,3-4,6\tabcellsep >4,6\\ Ig?, g/l\tabcellsep 0,5-1,1\tabcellsep <0,5\tabcellsep 2,1-2,6\tabcellsep >2,6\\ IgG, g/l\tabcellsep 10,8-14,4\tabcellsep <10,8\tabcellsep 14,4-18,0\tabcellsep >18,0\\ CIC, CU\tabcellsep 9,1-18,3\tabcellsep <9,1\tabcellsep 36,7-45,9\tabcellsep >45,9\\ MWM, CU\tabcellsep 1,9-3,7\tabcellsep <1,9\tabcellsep 7,3-9,1\tabcellsep >9,1\\ PhI, \%\tabcellsep 24,3-48,4\tabcellsep <24,3\tabcellsep 96,6-120,7\tabcellsep >120,7\\ PhN, number of bacteria\textbackslash Nph\tabcellsep 2,4-4,7\tabcellsep <2,4\tabcellsep 9,3-11,6\tabcellsep >11,6\\ NBTsp, \%\tabcellsep 2,9-5,7\tabcellsep <2,9\tabcellsep 11,3-14,1\tabcellsep >14,1\\ NBTac, \%\tabcellsep 7,5-15,0\tabcellsep <7,5\tabcellsep 30,0-37,5\tabcellsep >37,5\\ IL4, pkg/ml\tabcellsep 6,6-13,1\tabcellsep <6,6\tabcellsep 26,1-32,6\tabcellsep >32,6\\ IL6, pkg/ml\tabcellsep 5,5-10,9\tabcellsep <5,5\tabcellsep 21,7-27,1\tabcellsep >27,1\\ IL8, pkg/ml\tabcellsep 4,7-9,4\tabcellsep <4,7\tabcellsep 18,8-23,5\tabcellsep >23,5\\ TNF, pkg/ml\tabcellsep 0,06-0,13\tabcellsep <0,06\tabcellsep 0,26-0,32\tabcellsep >0,32\\ Lymphocytes (CD95+), 10 9 /l\tabcellsep 0,02-0,05\tabcellsep <0,02\tabcellsep 0,11-0,14\tabcellsep >0,14\\ L (leucocytes), 10 9 /l\tabcellsep 1,3-2,7\tabcellsep <1,3\tabcellsep 5,5-6,9\tabcellsep >6,9\\ Lph (lymphocytes), \%\tabcellsep 13,8-27,5\tabcellsep <13,8\tabcellsep 54,9-68,6\tabcellsep >68,6\\ \tabcellsep 20,4-40,5\tabcellsep <20,4\tabcellsep 80,7-100,8\tabcellsep >100,8\\ \tabcellsep 0,64-1,27\tabcellsep <0,64\tabcellsep 2,53-3,2\tabcellsep >3,2\\ \tabcellsep 4,2-8,5\tabcellsep <4,2\tabcellsep 13,0-17,2\tabcellsep >17,2\\ \tabcellsep 4,3-8,4\tabcellsep <4,3\tabcellsep 16,6-20,7\tabcellsep >20,7\end{longtable} \par \caption{\label{tab_5}Table 7 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Dysbacteriosis]{b6}\label{b6} \textit{}, Dysbacteriosis . \bibitem[Dysnucleotidosis]{b10}\label{b10} \textit{}, Dysnucleotidosis . \bibitem[Thymomegaly]{b20}\label{b20} \textit{}, Hyperplasia Thymomegaly . (or hypoplasia of the thymus in children) \bibitem[Non-Hodgkin]{b23}\label{b23} \textit{}, Non-Hodgkin . (s lymphomas) \bibitem[Burkitt's Lymphoma]{b24}\label{b24} \textit{}, Burkitt's Lymphoma . \bibitem[ Sarcoidosis]{b25}\label{b25} \textit{}, \textit{Sarcoidosis} \bibitem[Macroglobulinemia]{b26}\label{b26} \textit{}, Macroglobulinemia . \bibitem[Moscow and House ()]{b32}\label{b32} \textit{}, Publishing Moscow , House . \textit{Medical Information Agency} 2009. p. 711. \bibitem[Zemskov et al. ()]{b43}\label{b43} \textit{A method for selecting options in the treatment of nonspecific inflammatory lung diseases. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , M A Zemskov , Popov , Vi , A V Likhachev , V I Zoloedov . 2015619428. 2015. Russia. (Published on 03.09.) \bibitem[Lvovich et al. ()]{b46}\label{b46} \textit{A program for calculating a personal formula for immune system disorders in various diseases. Certificate of state registration of software for the Electronic Computing Machine}, I Y Lvovich , A M Zemskov , M A Lutskiy , Etc . 201861202. 2018. Russia. (Published 09.02) \bibitem[Activation of the complement system with accumulation (???, ?2?, ?4?, ?5?)]{b7}\label{b7} \textit{Activation of the complement system with accumulation (???, ?2?, ?4?, ?5?)}, \bibitem[Allergic reactions to insect bites]{b2}\label{b2} \textit{Allergic reactions to insect bites}, (contact with plants, odors, dyes, cosmetics, house dust, chemicals, bio-preparations, precious metals) \bibitem[Zemskov et al. ()]{b41}\label{b41} \textit{An additional method for diagnosing the pathogenesis of pyo-inflammatory diseases. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , T A Berezhnova , Ya V Kulintsova , V A Zemskova . 2018616529. 2018. Russia. (Published on 14.09) \bibitem[Autoimmune, Immunocomplex Syndrome 1. Diseases with an autoimmune component (hemolytic anemia, systemic lupus erythematosus, pernicious anemia, Sjogren's syndrome, Behcet's disease, Goodpasture's syndrome, systemic vasculitis Disorders of the antioxidant system. IX]{b11}\label{b11} ‘Autoimmune, Immunocomplex Syndrome 1. Diseases with an autoimmune component (hemolytic anemia, systemic lupus erythematosus, pernicious anemia, Sjogren's syndrome, Behcet's disease, Goodpasture's syndrome, systemic vasculitis’. \textit{Disorders of the antioxidant system. IX}, (s granulomatosis) \bibitem[Cold allergy. VII. Pseudo-allergic Syndrome 1. Violations of the diet (citrus fruits, fish, potatoes, cheese, chocolate)]{b4}\label{b4} \textit{Cold allergy. VII. Pseudo-allergic Syndrome 1. Violations of the diet (citrus fruits, fish, potatoes, cheese, chocolate)}, \bibitem[Zemskov et al. ()]{b29}\label{b29} \textit{Cours of lectures on clinical immunophysiology}, A M Zemskov , I E Esaulenko , V A Chereshnev , V M Zemskov , S V Suchkov , V I Popov , V A Zemskova . 2017. Textbook. Voronezh, Publishing House: Ritm. p. 1048. \bibitem[Diseases of the endocrine system]{b17}\label{b17} \textit{Diseases of the endocrine system}, (chronic autoimmune thyroiditis) \bibitem[Diseases of the gastrointestinal tract (Crohn's disease, ulcerative colitis, active hepatitis]{b15}\label{b15} \textit{Diseases of the gastrointestinal tract (Crohn's disease, ulcerative colitis, active hepatitis}, (primary biliary cirrhosis) \bibitem[Kalinina et al. ()]{b44}\label{b44} ‘Diseases of the immune system’. N M Kalinina , S A Ketlinsky , S V Okovity , S N Shulemin . \textit{Diagnostics and pharmacotherapy}, 2008. Moscow, Publishing House: Eksmo. p. 494. \bibitem[Diseases with the presence of immune complexes (rheumatoid arthritis, ankylosing spondylitis, essential cryoglobulinemia, scleroderma]{b12}\label{b12} \textit{Diseases with the presence of immune complexes (rheumatoid arthritis, ankylosing spondylitis, essential cryoglobulinemia, scleroderma}, \bibitem[Disorders of intestinal absorption]{b5}\label{b5} \textit{Disorders of intestinal absorption}, \bibitem[Drug intolerance, vaccination reactions, iatrogenic diseases (serum sickness, D-penicillamine nephropathy, drug thrombocytopenia)]{b0}\label{b0} \textit{Drug intolerance, vaccination reactions, iatrogenic diseases (serum sickness, D-penicillamine nephropathy, drug thrombocytopenia)}, \bibitem[Zemskov et al. ()]{b30}\label{b30} \textit{Electronic software doctor's assistant for the diagnosis and treatment of immunological disorders. ?ertificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , V M Zemskov , M A Zemskov , V A Zemskova . 2016619036. 2016. Russia. (Published on 11.08.) \bibitem[Helminthic invasion]{b3}\label{b3} \textit{Helminthic invasion}, \bibitem[Kishkun]{b31}\label{b31} \textit{Immunological studies and diagnostic methods of infectious diseases in clinical practice}, A A Kishkun . \bibitem[Zemskov et al. ()]{b40}\label{b40} \textit{Laboratory markers in the diagnosis of purulent-inflammatory Computing Machine}, A M Zemskov , V A Zemskova , T A Berezhnova , Y A Kulintsova . 2017662910. 2017. Russia. (Published on 21.11.) \bibitem[Lymphadenopathy, chronic tonsillitis, hypoplasia of lymph nodes]{b19}\label{b19} \textit{Lymphadenopathy, chronic tonsillitis, hypoplasia of lymph nodes}, \bibitem[Lymphogranulomatosis (Hodgkin's disease)]{b22}\label{b22} \textit{Lymphogranulomatosis (Hodgkin's disease)}, \bibitem[Pokrovsky ()]{b33}\label{b33} ‘Manual for physicians of general clinical immunology, allergology, immunogenetics, and immunopharmacology’. V I Pokrovsky . \textit{Triada-X} 2005. 2 p. 517. \bibitem[Neurological diseases (subacute sclerosing panencephalitis, amyotrophic lateral sclerosis, multiple sclerosis]{b16}\label{b16} \textit{Neurological diseases (subacute sclerosing panencephalitis, amyotrophic lateral sclerosis, multiple sclerosis}, \bibitem[Zemskov et al. ()]{b37}\label{b37} \textit{Problems of clinical immunology in the 21 st Century -II. Natural and drug regulation mechanisms of immunological homeostasis}, A M Zemskov , V A Chereshnev , A Revishvili , Sh , V M Zemskov , V I Popov , V A Zemskova . 2018. Moscow, Publishing House: Scientific Book. p. 286. \bibitem[Zemskov et al. ()]{b36}\label{b36} \textit{Program choice of options for purulent-inflammatory diseases. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , V M Zemskov , M A Zemskov , V A Zemskova , Etc . 2014660956. 2014. Russia. (Published on 20.10.) \bibitem[Reaction to medications -local anesthetics, X-ray contrast agents, carrying out physiotherapy VIII. Metabolic Syndrome]{b8}\label{b8} \textit{Reaction to medications -local anesthetics, X-ray contrast agents, carrying out physiotherapy VIII. Metabolic Syndrome}, \bibitem[Renal diseases (acute glomerulonephritis, Berger's disease, renal transplant)]{b13}\label{b13} \textit{Renal diseases (acute glomerulonephritis, Berger's disease, renal transplant)}, \bibitem[Zemskov et al. ()]{b34}\label{b34} \textit{Selection of options for differentiated auxiliary immunotherapy based on the results prelaboratory examination. ?ertificate of state registration of software the Electronic Computing Machine}, A M Zemskov , V M Zemskov , M A Zemskov , V A Zemskova , Etc . 2014619643. 2014. Russia. (Published on 18.09.) \bibitem[Skin diseases (dermatitis herpetiformis, pemphigus, pemphigoid)]{b14}\label{b14} \textit{Skin diseases (dermatitis herpetiformis, pemphigus, pemphigoid)}, \bibitem[Lymphoproliferative]{b18}\label{b18} \textit{Syndrome 1. Symptomatic (secondary) lymphoproliferative syndrome}, X Lymphoproliferative . \bibitem[Xi]{b28}\label{b28} \textit{Syndrome of Concomitant Chronic, Combined Diseases, and Conditions}, Xi . \bibitem[The actual metabolic syndrome (abdominal obesity, type 2 diabetes mellitus or impaired glucose tolerance, arterial hypertension, dyslipidemia)]{b9}\label{b9} \textit{The actual metabolic syndrome (abdominal obesity, type 2 diabetes mellitus or impaired glucose tolerance, arterial hypertension, dyslipidemia)}, \bibitem[Zemskov et al. ()]{b39}\label{b39} \textit{The choice of differentiated immunotion of software for the Electronic Computing Machine}, A M Zemskov , V A Zemskova , Etc . 2015614977. 2015. Russia. (Published 05.05.) \bibitem[Zemskov et al. ()]{b35}\label{b35} \textit{The choice of options for differentiated immunotherapy is based on generalized laboratory diagnostics in patients with immune disorders. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , V A Zemskova , Etc . 2015612811. 2015. Russia. (Published on 26.02.) \bibitem[Zemskov et al. ()]{b42}\label{b42} \textit{The choice of options rendered immunotherapy according to the detailed immunological analysis. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , V A Zemskova , M A Zemskov , Etc . 2014619846. 2014. Russia. (Published 23.09.) \bibitem[Zemskov and Zemskova ()]{b38}\label{b38} \textit{The choice of treatment options for infections based on the immunosuppressive or immunostimulating effect of antibiotics. Certificate of state registration of software for the Electronic Computing Machine}, A M Zemskov , V A Zemskova . 2015614569. 2015. Russia. (Published on 21.04.) \bibitem[Pokrovsky ()]{b45}\label{b45} \textit{The national conception of prevention of infections associated with first aid rendering and informational material based on its provisions}, V I Pokrovsky . 2012. Russia: Nizhny Novgorod, Publishing House: Remedium Privolzhye. p. 84. \bibitem[The presence of any malignant neoplasms]{b27}\label{b27} \textit{The presence of any malignant neoplasms}, \bibitem[Transfer in anamnesis of anaphylactic shocks, Quincke's edema, Lyell's syndrome, Stephen-Johnson's, drug-disease, and other allergic reactions]{b1}\label{b1} \textit{Transfer in anamnesis of anaphylactic shocks, Quincke's edema, Lyell's syndrome, Stephen-Johnson's, drug-disease, and other allergic reactions}, \bibitem[Transferring a history of infectious mononucleosis]{b21}\label{b21} \textit{Transferring a history of infectious mononucleosis}, \end{bibitemlist} \end{document}